PARP產品特點
|
· Fewer user steps
· Pre-coated 96 well capture antibody plates
· High signal to noise ratio
· Detection sensitivity of 2 pg/ml of PAR
· Broad linear dynamic range to 1,000 pg/ml
· Reduced inter-assay variability
· Commercially available validated assay that measures drug action on PARP in both in vivo and in vitro settings
| ||
PARP產品應用:
|
· Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
· Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
· Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
· Facilitating development of PARP and PARG targeted therapeutics
| ||
Components:
|
Part #
|
Component
|
Size
|
4520-096-01
|
PAR Standard, 25 pg/μl
|
5 x 20 μl
| |
4520-096-02
|
Sample Buffer
|
20 ml
| |
4520-096-03
|
PAR Polyclonal Detecting Antibody
|
30 μl
| |
4520-096-04
|
Goat anti-Rabbit IgG-HRP
|
30 μl
| |
PARP PeroxyGlow™ A
|
6 ml
| ||
PARP PeroxyGlow™ B
|
6 ml
| ||
4520-096-05
|
Cell Lysis Reagent
|
30 ml
| |
4520-096-06
|
DNase 1, 2 Units/μl
|
60 μl
| |
4520-096-07
|
100X Magnesium Cation
|
500 μl
| |
4520-096-P
|
Pre-coated white 96-stripwell plate, and 5 sealers
|
1 plate
| |
4520-096-08
|
Jurkat Cell Lysate Standard Control, Low
|
600 μl
| |
4520-096-09
|
Jurkat Cell Lysate Standard Control, Medium
|
600 μl
| |
4520-096-10
|
Jurkat Cell Lysate Standard Control, High
|
600 μl
| |
4520-096-11
|
Antibody Diluent
|
15 ml
| |
4520-096-12
|
20% (w/v) SDS
|
1 ml
| |
Storage:
|
Components are stored at -80°C , -20°C , 4°C , and room temperature
| ||
References:
|
1. Virag, L., and Szabo, C. 2002. The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacological Reviews 54:375-429.
2. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83. 3. Curtin NJ. 2005. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20. 4. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-85. | ||
CometAssay® 
» Angiogenesis/Cell Differentiation
Immunogen:
|
The antibody was raised against UV irradiated calf thymus ssDNA conjugated to methylated BSA (mBSA) and UV irradiated poly dT-mBSA complex.
|
Source:
|
Mouse
|
Specificity:
|
The anti-UVssDNA antibody recognizes (6-4) dipyrimidine photoproducts in single-stranded DNA (prepared by denaturing isolated DNA). The antibody can detect (6-4) photoproducts in sequences as short as 4 base pairs.
|
Preparation:
|
The antibody is provided as purified ascites containing 0.01% BSA.
|
Applications:
|
· ELISA
· Indirect in situ immunofluorescence
· CometAssay®
|
Storage:
|
Stored at 4°C . For long term storage, freeze in working aliquots at -20°C in a manual defrost freezer to avoid repeated freeze-thawings.
|
